Compare
Taysha Gene Therapies, Inc. vs Curis Inc vs Alpha Cognition Inc. vs TScan Therapeutics, Inc.
| Latest fiscal year | Taysha Gene Therapies, Inc. TSHA | Curis Inc CRIS | Alpha Cognition Inc. ACOG | TScan Therapeutics, Inc. TCRX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $9.77M | $9.44M | $10.22M | $10.32M |
| Revenue growth (YoY) | +17.3% | -13.4% | n/a | +266.7% |
| Gross margin | n/a | n/a | 94.1% (computed) | n/a |
| Operating margin | n/m | -60.5% | -221.7% | n/m |
| Net margin | n/m | -80.3% | -202.2% | n/m |
| Net income | -$109.00M | -$7.58M | -$20.67M | -$129.77M |
| EPS (Diluted) | -$0.34 | -$0.58 | -$1.18 | -$1.00 |
| Operating cash flow | -$93.09M | -$27.20M | -$20.38M | -$135.32M |
| Free cash flow | -$93.83M | n/a | -$20.67M | -$139.73M |
| Cash & equivalents | $319.77M | $5.06M | $66.05M | $152.41M |
| Total assets | $343.32M | $19.97M | $79.73M | $228.79M |
| Total liabilities | $96.38M | $14.50M | $17.20M | $105.67M |
| Shareholders' equity | $246.94M | $5.46M | $62.53M | $123.12M |
| Return on year-end equity | -44.1% | -138.8% | -33.1% | -105.4% |
| Shares outstanding | 285.05M | 12.93M | 21.74M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Taysha Gene Therapies, Inc. | Curis Inc | Alpha Cognition Inc. | TScan Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $9.77M Ended 2025-12-31 | $9.44M Ended 2025-12-31 | $10.22M Ended 2025-12-31 | $10.32M Ended 2025-12-31 |
| 1 year earlier | $8.33M Ended 2024-12-31 | $10.91M Ended 2024-12-31 | n/a | $2.82M Ended 2024-12-31 |
| 2 years earlier | $15.45M Ended 2023-12-31 | $10.02M Ended 2023-12-31 | n/a | $21.05M Ended 2023-12-31 |
| 3 years earlier | $2.50M Ended 2022-12-31 | $10.16M Ended 2022-12-31 | n/a | $13.54M Ended 2022-12-31 |
| 4 years earlier | n/a | $10.65M Ended 2021-12-31 | n/a | $10.14M Ended 2021-12-31 |